Plus Therapeutics (NASDAQ:PSTV) Given “Buy” Rating at HC Wainwright

HC Wainwright reissued their buy rating on shares of Plus Therapeutics (NASDAQ:PSTV) in a report released on Friday, Benzinga reports. HC Wainwright currently has a $8.00 price target on the stock. HC Wainwright also issued estimates for Plus Therapeutics’ Q1 2025 earnings at ($0.30) EPS, Q2 2025 earnings at ($0.32) EPS, Q3 2025 earnings at ($0.35) EPS and Q4 2025 earnings at ($0.58) EPS.

Plus Therapeutics Price Performance

Shares of NASDAQ:PSTV opened at $1.36 on Friday. The business’s 50 day moving average price is $1.72 and its 200-day moving average price is $1.87. Plus Therapeutics has a 1 year low of $0.97 and a 1 year high of $3.21. The firm has a market capitalization of $7.76 million, a price-to-earnings ratio of -0.45 and a beta of 0.54.

Institutional Trading of Plus Therapeutics

An institutional investor recently bought a new position in Plus Therapeutics stock. AIGH Capital Management LLC purchased a new position in shares of Plus Therapeutics, Inc. (NASDAQ:PSTV) in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 568,681 shares of the company’s stock, valued at approximately $836,000. AIGH Capital Management LLC owned about 9.98% of Plus Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 3.28% of the company’s stock.

About Plus Therapeutics

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.